• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

July 15, 2019
Company Drug/Device Medical Condition Status

Emmaus Life Sciences, Inc.

pharmaceutical-grade L-glutamine (PGLG)

diverticulosis

Phase 1 trial initiated enrolling 10 patients at multiple sites

Enanta Pharmaceuticals, Inc.

EDP-514

hepatitis B virus (HBV)

Phase 1a/1b trial initiated enrolling 98 subjects

Neurovive Pharmaceutical AB

KL1333

mitochondrial disease

Phase 1a/1b trial initiated enrolling healthy subjects in the UK after successful completion of the first stage of enrollment

Auris Medical
Holding Ltd.

AM-201

antipsychotic-induced weight gain and somnolence

Phase 1b trial initiated enrolling healthy volunteer subjects in Europe

4D pharma plc

MRx-4DP0004

asthma

Phase 1/2 trial initiated enrolling 90 subjects not adequately controlled on their current inhaler maintenance therapy

Vedanta Biosciences

VE416

peanut allergy

Phase 1b/2 trial initiated enrolling 40 subjects 12 years of age and older at MassGeneral Hospital for Children in Boston

ActoBio Therapeutics, Inc.

AG019

early-onset type 1 diabetes (T1D)

Phase 1b/2a trial initiated enrolling subjects 12 to 17 years of age

ActoBio Therapeutics, Inc.

AG019 combined with teplizumab (PRV-031)

early-onset type 1 diabetes (T1D)

Phase 1b/2a trial initiated enrolling adult subjects

Biohaven Pharmaceutical Holding Company Ltd.

rimegepant

treatment refractory trigeminal neuralgia

Phase 2 trial initiated enrolling subjects at Johns Hopkins Medical Center

GlaxoSmithKline

otilimab

moderate to severe rheumatoid arthritis (RA)

Phase 3 trial initiated

BiondVax Pharmaceuticals Ltd.

M-001

influenza

Phase 3 trial initiated

Alexion Pharmaceuticals, Inc.

SOLIRIS (eculizumab)

neuromyelitis optica spectrum disorder (NMOSD) in adult subjects who are anti-aquaporin-4 (AQP4) antibody positive

Approval granted by the FDA

Janssen

DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone (Rd)

subjects with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT)

Approval granted by the FDA

Pfizer

ZIRABEV (bevacizumab-bvzr)

metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent or metastatic cervical cancer

Approval granted by the FDA

Janssen

Genmab

Darzalex (daratumumab) in combination with lenalidomide and dexamethasone as a first-line treatment

multiple myeloma subjects who are ineligible for autologous stem cell transplant (ASCT)

Approval granted by the FDA

Alexion Pharmaceuticals

Soliris (eculizumab)

neuromyelitis optica spectrum disorder (NMOSD) in adult subjects that express a specific biomarker

Approval granted by the FDA

Teva Pharmaceuticals

1% Sodium Hyaluronate

osteoarthritis (OA) of the knee in subjects who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen)

Approval granted by the FDA

Retrophin

Thiola EC (tiopronin) 100 mg and 300 mg tablets

cystinuria

Approval granted by the FDA

Grifols

Xembify 20% subcutaneous immunoglobulin

primary immunodeficiencies

Approval granted by the FDA

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing